Peritumoral inflammatory reaction in colon cancer Histological and immunohistochemical study

Romanian Journal of Morphology and Embryology

Volumn 55, Issue 4, 2014, Pages 1429-1435

  Mogoantă, Stelian Ştefăniţă ^a   Lungu, Corina ^a   Ilie, Cătălin ^a   Albu, Dinu Florin ^b   Totolici, Bogdan ^c   Neamţu, Carmen ^c   Mitruţ, Paul ^a   Dogaru, Carmen Adriana ^a   Turculeanu, Adriana ^a  

^a UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c VASILE GOLDIS WESTERN UNIVERSITY OF ARAD   (Romania)

Author keywords

Chronic inflammation; Colon cancer; Inflammatory cells; Macrophages; Mast cells

Indexed keywords

CD34 ANTIGEN;

B LYMPHOCYTE; CELL DIFFERENTIATION; COLON TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INFLAMMATION; MAST CELL; METABOLISM; NECROSIS; PATHOLOGY; STROMA CELL; VASCULARIZATION;

ANTIGENS, CD34; B-LYMPHOCYTES; CELL DIFFERENTIATION; COLONIC NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MAST CELLS; NECROSIS; STROMAL CELLS;

EID: 84920440159     PISSN: 12200522     EISSN: 20668279     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Tan C, Du X, KRAS mutation testing in metastatic colorectal cancer, World J Gastroenterol, 2012, 18(37):5171-5180.
2. Parkin DM, Bray F, Ferlay J, Pisani P, Global cancer statistics, 2002, CA Cancer J Clin, 2005, 55(2):74-108.
3. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ, Cancer statistics, 2005, CA Cancer J Clin, 2005, 55(1):10-30.
4. Jemal A, Siegel R, Xu J, Ward E, Cancer statistics, 2010, CA Cancer J Clin, 2010, 60(5):277-300.
5. Balkwill F, Mantovani A, Inflammation and cancer: back to Virchow? Lancet, 2001, 357(9255):539-545.
6. Coussens LM, Werb Z, Inflammation and cancer, Nature, 2002, 420(6917):860-867.
7. Philip M, Rowley DA, Schreiber H, Inflammation as a tumor promoter in cancer induction, Semin Cancer Biol, 2004, 14(6):433-439.
8. Triantafillidis JK, Nasioulas G, Kosmidis PA, Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies, Anticancer Res, 2009, 29(7):2727-2737.
9. Choi KW, Hong SW, Chang YG, Lee WY, Lee B, Paik IW, Lee H, Inflammation-based score (Glasgow prognostic score) as an independent prognostic factor in colorectal cancer patients, Ann Surg Treat Res, 2014, 86(6):309-313.
10. Bae SI, Kim YS, Colon cancer screening and surveillance in inflammatory bowel disease, Clin Endosc, 2014, 47(6):509-515.
11. Mantovani A, Allavena P, Sica A, Balkwill F, Cancer-related inflammation, Nature, 2008, 454(7203):436-444.
12. Gurzu S, Szentirmay Z, Jung I, Molecular classification of colorectal cancer: a dream that can become a reality, Rom J Morphol Embryol, 2013, 54(2):241-245.
13. Lu H, Ouyang W, Huang C, Inflammation, a key event in cancer development, Mol Cancer Res, 2006, 4(4):221-233.
14. Yang CR, Hsieh SL, Ho FM, Lin WW, Decoy receptor 3 increases monocyte adhesion to endothelial cells via NFkappa B-dependent up-regulation of intercellular adhesion molecule-1, VCAM-1, and IL-8 expression, J Immunol, 2005, 174(3):1647-1656.
15. Atreya I, Neurath MF, Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies, Expert Rev Anticancer Ther, 2008, 8(4):561-572.
16. Nathan C, Points of control in inflammation, Nature, 2002, 420(6917):846-852.
17. Maeda H, Akaike T, Nitric oxide and oxygen radicals in infection, inflammation, and cancer, Biochemistry (Mosc), 1998, 63(7):854-865.
18. Itzkowitz SH, Yio X, Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation, Am J Physiol Gastrointest Liver Physiol, 2004, 287(1):G7-G17.
19. Pollard JW, Tumour-educated macrophages promote tumour progression and metastasis, Nat Rev Cancer, 2004, 4(1): 71-78.
20. Elgert KD, Alleva DG, Mullins DW, Tumor-induced immune dysfunction: the macrophage connection, J Leukoc Biol, 1998, 64(3):275-290.
21. Bando H, Toi M, Tumor angiogenesis, macrophages, and cytokines, Adv Exp Med Biol, 2000, 476:267-284.
22. Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL, Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer, J Pathol, 2001, 195(2):236-243.
23. Grimshaw MJ, Wilson JL, Balkwill FR, Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors, Eur J Immunol, 2002, 32(9):2393-2400.
24. Shea-Donohue T, Stiltz J, Zhao A, Notari L, Mast cells, Curr Gastroenterol Rep, 2010, 12(5):349-357.
25. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M, Mast cells as “tunable” effector and immunoregulatory cells: recent advances, Annu Rev Immunol, 2005, 23:749-786.
26. Nakayama T, Yao L, Tosato G, Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors, J Clin Invest, 2004, 114(9):1317-1325.
27. Theoharides TC, Conti P, Mast cells: the Jekyll and Hyde of tumor growth, Trends Immunol, 2004, 25(5):235-241.
28. Ribatti D, Crivellato E, Mast cells, angiogenesis and cancer, Adv Exp Med Biol, 2011, 716:270-288.
29. Ranieri G, Hot topic: targeting tumor angiogenesis: an update, Curr Med Chem, 2012, 19(7):937.
30. Ribatti D, Ranieri G, Basile A, Azzariti A, Paradiso A, Vacca A, Tumor endothelial markers as a target in cancer, Expert Opin Ther Targets, 2012, 16(12):1215-1225.
31. Liu Y, Mueller BM, Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDAMB-231 cells via MAPK pathways, Biochem Biophys Res Commun, 2006, 344(4):1263-1270.
32. Terzić J, Grivennikov S, Karin E, Karin M, Inflammation and colon cancer, Gastroenterology, 2010, 138(6):2101-2114.e5.
33. Trinchieri G, Cancer and inflammation: an old intuition with rapidly evolving new concepts, Annu Rev Immunol, 2012, 30: 677-706.